Simcere Pharmaceutical Group Limited Stock
Stocks
2096
HK0000658531
Pharmaceuticals
OTC Markets Traded|
Delayed
Hong Kong S.E.
10:53:31 16/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 10.52 HKD | -0.57% |
|
-6.07% | -12.11% |
| 11-10 | Simcere Pharma Gets China Nod for Autoimmune Disease Drug Trial | MT |
| 11-09 | Simcere Pharmaceutical Gets Nod for Inflammatory Bowel Disease Drug in Germany | MT |
| Market Cap | 3.46B 27.17B 3.14B 2.9B 2.62B 4.94B 327B 5.11B 34.87B 13.83B 174B 13B 12.72B 554B | P/E 2026 * |
13.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 3.26B 25.61B 2.96B 2.74B 2.47B 4.65B 308B 4.82B 32.87B 13.03B 164B 12.25B 11.99B 522B | EV / Sales 2026 * |
2.14x | EV / Sales 2027 * | 1.89x |
| Free-Float |
33.7% | Yield 2026 * |
4.01% | Yield 2027 * | 4.55% |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2096 | Delayed | |
| SMHGF | Delayed | ||
| S2P | Real-time | ||
| S2P | Delayed | ||
| S2P | Delayed | ||
| S2P | Real-time |
| 1 day | -1.23% | ||
| 1 week | -6.70% | ||
| Current month | +3.06% | ||
| 1 month | -5.17% | ||
| 3 months | -15.52% | ||
| 6 months | -6.53% | ||
| Current year | -12.70% |
| 1 week | 10.42 | 11.33 | |
| 1 month | 9.86 | 11.38 | |
| Current year | 9.07 | 14.28 | |
| 1 year | 9.07 | 14.34 | |
| 3 years | 4.94 | 15.08 | |
| 5 years | 4.94 | 15.08 | |
| 10 years | 4.94 | 15.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CEO | Chief Executive Officer | 63 | 20/08/2026 |
Yunshu Zhou
CEO | Chief Executive Officer | 54 | 25/03/2026 |
Yushan Wan
DFI | Director of Finance/CFO | 55 | 19/11/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CHM | Chairman | 63 | 08/10/2012 |
Yushan Wan
BRD | Director/Board Member | 55 | 19/11/2019 |
Renhong Tang
BRD | Director/Board Member | 46 | 01/11/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/10/26 | Other | Chief Executive Officer | 200,000 | 0.0078% | ||
| 28/10/26 | Other | Director | 200,000 | 0.0078% | ||
| 20/8/26 | Other | Chairperson | -3,000,000 | 0.1168% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.66% | -6.70% | -24.17% | +45.14% | 3.46B | ||
| +1.26% | +6.61% | +40.79% | +145.27% | 1,286B | ||
| +0.79% | +3.45% | +45.84% | +92.04% | 688B | ||
| +0.20% | +1.28% | +26.97% | +114.41% | 521B | ||
| -0.44% | +3.69% | +41.45% | +70.04% | 386B | ||
| +0.55% | +0.70% | +59.02% | +45.79% | 364B | ||
| -0.12% | +0.74% | +28.39% | +60.32% | 302B | ||
| +0.37% | +0.37% | +3.33% | +38.57% | 287B | ||
| -0.30% | +1.14% | +38.29% | +70.56% | 252B | ||
| +0.08% | +0.71% | +34.44% | +123.99% | 208B | ||
| Average | +0.12% | +1.41% | +29.44% | +80.61% | 430B | |
| Weighted average by Cap. | +0.54% | +3.25% | +37.65% | +99.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.52B 11.95B 1.38B 1.28B 1.15B 2.17B 144B 2.25B 15.34B 6.08B 76.74B 5.72B 5.6B 244B | 1.76B 13.81B 1.6B 1.48B 1.33B 2.51B 166B 2.6B 17.72B 7.03B 88.66B 6.61B 6.47B 281B |
| Net income | 257M 2.02B 233M 216M 195M 367M 24.25B 379M 2.59B 1.03B 12.95B 965M 945M 41.12B | 304M 2.39B 276M 255M 230M 433M 28.67B 449M 3.06B 1.21B 15.31B 1.14B 1.12B 48.61B |
| Net Debt | -199M -1.56B -180M -167M -150M -283M -18.75B -293M -2B -794M -10.02B -746M -731M -31.8B | -141M -1.11B -128M -118M -107M -201M -13.28B -208M -1.42B -562M -7.09B -529M -517M -22.52B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/11/26 | HK$10.52 | -0.57% | 504,000 |
| 13/11/26 | HK$10.58 | -2.85% | 2,365,537 |
| 12/11/26 | HK$10.89 | -0.18% | 2,500,600 |
| 11/11/26 | HK$10.91 | -1.09% | 3,201,000 |
| 10/11/26 | HK$11.03 | -1.52% | 2,523,540 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2096 Stock
Select your edition
All financial news and data tailored to specific country editions
















